Vertex Fails to Convince UK Watchdog of CRISPR Therapy Casgevy’s Value
By Nick Paul Taylor,
BioSpace
| 03. 14. 2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene autotemcel) when the Medicines and Healthcare products Regulatory Agency approved the treatment in November 2023. However, regulatory approval is just the first of two key steps to reaching patients in the U.K. Vertex must also show the therapy is cost-effective before it can be used routinely by the National Health Service (NHS).
The U.K. National Institute for Health and Care Excellence (NICE) recommended against the use of Casgevy in sickle cell disease in draft guidance. The therapy has a list price of $2.2 million in the U.S. but NICE’s guidance says the U.K. price is “commercial in confidence.” Vertex’s justification for the cost rests on the potential for a one-time treatment with Casgevy to provide a functional cure for sickle cell disease.
Currently, NICE’s cost-effectiveness estimate for Casgevy exceeds the threshold it normally views as a good use of the...
Related Articles
By Emma McDonald Kennedy
| 07.11.2024
Louise Perry’s recent article in The Spectator cautions against “The quiet return of eugenics,” a threat she locates in preimplantation genetic testing for polygenic disorders. The technology is billed as a way for parents undergoing IVF to select which embryo to implant based on information about each embryo’s genetic risk factors and traits. These reports, she says, give parents “a very full picture of the adult that embryo could become”––from their child’s risk of developing different diseases to their “likely...
Photo by TeggorMindFish via Wikimedia Commons, licensed under
the Creative Commons Attribution-Share Alike 4.0 International license
Prophets of techno-paradise tend to bloom and then fade but not necessarily disappear. Malcolm and Simone Collins, a husband and wife team, have been on quite a roll for a couple of years. However, their time in the spotlight may at last be coming to a close, after a report revealed their parenting style.
The Collins family have already featured on this...
GATTACA was released in 1997, but — remarkably — is even more relevant now than it was then, as the technologies whose social implications it explores have developed considerably.
On Thursday, June 13, the California Film Institute presented GATTACA to a sold-out house at the Christopher B. Smith Rafael Film Center as part of their Science on Screen series. CGS Associate Director Katie Hasson offered framing for the film and participated in a Q+A discussion.
The film’s plot explicitly involves...